Bringing the Oncology Community Together

Dr. Gandara Discusses Molecular Testing for NSCLC

David R. Gandara, MD
Published Online: Thursday, August 9, 2012
David R. Gandara, MD, Director, Thoracic Oncology Program, University of California, Davis Comprehensive Cancer Center, discusses the different types of molecular testing procedures available for patients with non-small cell lung cancer (NSCLC).

Several driver mutations and molecular abnormalities play an important role in determining the most appropriate therapy, for patients with NSCLC. Traditionally, testing for these aberrations has been done sequentially; however, a newer method known as multiplexing measures for several abnormalities simultaneously, in a single assay. Gandara notes that multiplexing is more cost effective, better utilizes the biopsy, and avoids the long delays that may accompany sequential testing.

Gandara uses KRAS mutations, as an example of the benefits of multiplexing. In the past, KRAS status was used primarily to assess sensitivity to erlotinib or chemotherapy. Currently, there are classes of agents being investigated, such as MEK inhibitors, which are active in patients with KRAS mutations. Knowing the status of KRAS early in the treatment process may guide the decision to enroll the patient in a clinical trial. Multiplexing allows physicians to assess KRAS status at the same time as other biological markers.

Related Articles
Pancoast Tumors of the Lung: Improved Results
Every patient with a pancoast tumor of the lung should be evaluated by a Pancoast-experienced thoracic surgeon (and neurosurgeon) before ruling out surgery, and before starting induction therapy.
Next-Generation Targeted Therapies in NSCLC
In this segment, panelists discuss the number of early-phase clinical trials that have demonstrated impressive efficacy for next-generation ALK and EGFR inhibitors for patients with non-small cell lung cancer.
PD-L1 Predictive of Response to MK-3475 in Melanoma and NSCLC
PD-L1 levels adequately predict response and clinical outcomes for PD-1 inhibitor MK-3475 in patients with non-small cell lung cancer (NSCLC) and melanoma
Most Popular Right Now
More Reading
External Resources

American Journal of Managed Care
HCPLive
PainLive
Pharmacy Times
Physicians' Education Resource
Physician's Money Digest
Specialty Pharmacy Times
TargetedOnc
OncLive Resources

Archives
Blogs
OncLive TV
Oncology Nurses
Publications
Specialties
Web Exclusives


About Us
Advertise
Advisory Board
Contact Us
Forgot Password
Privacy Policy
Terms & Conditions
Intellisphere, LLC
666 Plainsboro Road
Building 300
Plainsboro, NJ 08536
P: 609-716-7777
F: 609-716-4747

Copyright OncLive 2006-2014
Intellisphere, LLC. All Rights Reserved.